Sykehuset Telemark HF
- Address
- Ulefossvegen 55, 3710 Skien, Norway
Sykehuset Telemark HF - Multidisciplinary Clinical Research Center
Sykehuset Telemark HF is a comprehensive clinical research center conducting diverse therapeutic investigations across multiple medical specialties. The center demonstrates particular strength in precision oncology, neurological disorders, and innovative treatment approaches for both acute and chronic conditions.
- Precision medicine and targeted cancer therapies for advanced malignancies, including rare and hard-to-treat cancers with genomic-guided treatment strategies
- Neurological disease research encompassing multiple sclerosis, amyotrophic lateral sclerosis (ALS), and acute sudden sensorineural hearing loss
- Pain management and palliative care studies, including novel approaches to opioid therapy and analgesic optimization in metastatic cancer
- Cardiovascular disease in special populations, particularly atherosclerotic disease in end-stage kidney disease (ESKD) patients undergoing dialysis
The center's research portfolio extends to addiction medicine with studies on benzodiazepine dependence in opioid agonist therapy, infectious disease management including antibiotic stewardship in viral respiratory infections, and specialized surgical applications. Additional expertise includes reproductive medicine, ophthalmological emergencies such as central retinal artery occlusion, hyperbaric oxygen therapy, and autoimmune rheumatic diseases with pulmonary complications. This broad investigational scope positions Sykehuset Telemark HF as a versatile research institution committed to advancing evidence-based care across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Oslo University Hospital HF6active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF7trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sykehuset Telemark HF
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years | Helse Bergen HF | Phase III | Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 3 | Unknown | 2020-10-30 | 2025-06-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.